Shedding light on therapeutics in alopecia and their relevance to COVID-19

Nicole Fagan, Nekma Meah, Katherine York, Laita Bokhari, Godfrey Fletcher, Gang Chen, Desmond J. Tobin, Andrew Messenger, Alan D. Irvine, Rodney Sinclair, Dmitri Wall

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


As of July 9, 2020, there were more than 12 million confirmed cases of coronavirus disease 2019 (COVID-19) across the globe, with more than 550,000 deaths. Many European countries, including Belgium, the United Kingdom, Italy, and Spain, have had the highest numbers of fatalities per capita. This indicates the potential for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to overwhelm even the most advanced health care systems despite extreme societal interventions. Since its emergence, SARS-CoV-2 has disseminated across the globe, affecting the structure of global societies, infrastructure, and economies. Patients with alopecia are a diverse group who, for various indications, are prescribed a number of antimicrobials and antiandrogen treatments in addition to immunomodulatory therapies such as hydroxychloroquine, oral corticosteroids, and a range of broad immunosuppressants. These drugs are being scrutinized for their capacity to potentially affect SARS-CoV-2 outcomes. We examine these treatments and highlight the critical role that patient registries will play in generating real-world evidence to assess their impact on COVID-19 outcomes.

Original languageEnglish
Pages (from-to)76-83
Number of pages8
JournalClinics in Dermatology
Issue number1
Publication statusPublished - Jan 2021

Cite this